UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2201-13
Program Prior Authorization/Medical Necessity
Medication *Orencia® (abatacept)
*This program applies to the subcutaneous formulation of abatacept
P&T Approval Date 5/2020, 11/2020, 6/2021, 12/2021, 3/2022, 11/2022, 1/2023, 4/2023,
7/2023, 1/2024, 2/2024, 10/2024, 4/2025
Effective Date 6/1/2025
1. Background:
Orencia® (abatacept) is a selective T-cell costimulation modulator indicated for the treatment
of adult patients with moderately to severely active rheumatoid arthritis, patients 2 years of
age and older with moderately to severely active polyarticular juvenile idiopathic arthritis,
and patients 2 years of age and older with active psoriatic arthritis.
Concomitant used of Orencia with other immunosuppressives (e.g., biologic disease-
modifying antirheumatic drugs, Janus kinase (JAK) inhibitors) is not recommended.
2. Coverage Criteriaa:
A. Rheumatoid Arthritis (RA)
1. Initial Authorization
a. Orencia will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active rheumatoid arthritis
-AND-
(2) One of the following:
(a) Both of the following:
i. One of the following:
a. History of failure to a 3 month trial of one non-biologic disease
modifying anti-rheumatic drug (DMARD) [e.g., methotrexate,
leflunomide, sulfasalazine, hydroxychloroquine] at maximally
indicated doses, unless contraindicated or clinically significant
adverse effects are experienced (document drug, date, and duration of
trial)b
-OR-
b. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of rheumatoid arthritis as
© 2025 UnitedHealthcare Services, Inc.
1
documented by claims history or submission of medical records
(Document drug, date, and duration of therapy) [e.g., Cimzia
(certolizumab), adalimumab, Simponi (golimumab), Olumiant
(baricitinib), Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib),
Enbrel (etanercept)]
-AND-
ii. History of failure, contraindication, or intolerance to two of the following
preferred products (Document drug, date, and duration of trial):
a. One of the preferred adalimumab productsc
b. Cimzia (certolizumab)
c. Enbrel (etanercept)
d. Rinvoq (upadacitinib)
e. Simponi (golimumab)
f. Xeljanz/Xeljanz XR (tofacitinib)
-OR-
(b) Both of the following:
i. Patient is currently on Orencia therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
the prescriber’s office, or any form of assistance from the Bristol-
Myers Squibb sponsored Orencia® Co-Pay Program™ (e.g., sample
card which can be redeemed at a pharmacy for a free supply of
medication) as a means to establish as a current user of Orencia*
-AND-
(3) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
-AND-
(4) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
assistance from the Bristol-Myers Squibb sponsored Orencia® Co-Pay Program™ shall
be required to meet initial authorization criteria as if patient were new to therapy.
© 2025 UnitedHealthcare Services, Inc.
2
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
Authorization will be issued for 12 months.
B. Juvenile Idiopathic Arthritis (JIA)
1. Initial Authorization
a. Orencia will be approved based on all of the following criteria:
(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic
arthritis.
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
-AND-
(3) Prescribed by or in consultation with a rheumatologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
© 2025 UnitedHealthcare Services, Inc.
3
(golimumab), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
Authorization will be issued for 12 months.
C. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Orencia will be approved based on all of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
(a) Both of the following:
i. One of the following:
a. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
b. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of psoriatic arthritis as documented
by claims history or submission of medical records (Document drug,
date, and duration of therapy) [e.g., Cimzia (certolizumab),
adalimumab, Simponi (golimumab), ustekinumab, Tremfya
(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast),
Skyrizi (risankizumab), Enbrel (etanercept)]
-AND-
ii. One of the following:
a. History of failure, contraindication, or intolerance to two of the
following preferred products: (document drug, date, and duration of
trial)
1. One of the preferred adalimumab productsc
2. Cimzia (certolizumab)
3. Cosentyx (secukinumab)
4. Enbrel (etanercept)
5. Rinvoq (upadacitinib)
6. Simponi (golimumab)
7. Skyrizi (risankizumab-rzaa)
© 2025 UnitedHealthcare Services, Inc.
4
8. One of the preferred ustekinumab productsc
9. Tremfya (guselkumab)
10. Xeljanz/Xeljanz XR (tofacitinib)
-OR-
b. Both of the following:
1. Patient is less than 18 years of age
-AND-
2. History of failure, contraindication, or intolerance to one of the
preferred ustekinumab productsc ustekinumab or Enbrel
(etanercept) (document date and duration of trial)
-OR-
(b) Both of the following:
i. Patient is currently on Orencia therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in
the prescriber’s office, or any form of assistance from the Bristol-
Myers Squibb sponsored Orencia® Co-Pay Program™ (e.g., sample
card which can be redeemed at a pharmacy for a free supply of
medication) as a means to establish as a current user of Orencia*
-AND-
(3) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the receipt
of a manufacturer supplied sample at no cost in the prescriber’s office or any form of
© 2025 UnitedHealthcare Services, Inc.
5
assistance from the Bristol-Myers Squibb sponsored Orencia® Co-Pay Program™ shall
be required to meet initial authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Orencia will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Orencia therapy
-AND-
(2) Patient is not receiving Orencia in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), adalimumab, ustekinumab, Skyrizi (risankizumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
c For a list of preferred products please reference drug coverage tools.
3. Additional Clinical Rules:
• Supply limits may be in place.
The intravenous infusion is typically covered under the medical benefit. Please refer to the United
Healthcare Medical Benefit Drug Policy for Orencia.
4. References:
1. Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; October 2023.
2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical
practice guidelines based on published evidence and expert opinions. Joint Bone Spine
2006;73(4):388-95.
3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for
the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. Arthritis Rheum.
2016;68(1):1-26.
4. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol.
2016 May;68(5):1060-71.
5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of
psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
© 2025 UnitedHealthcare Services, Inc.
6
6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an
emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis
with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
10. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for
the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment
of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J
Am Acad Dermatol. 2011 Jul;65(1):137-74.
11. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the
management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis
2016;75:499-510.
Program Prior Authorization/Medical Necessity - Orencia (abatacept)
Change Control
5/2020 New program
11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.
Updated background and references.
6/2021 Removed prescriber requirement from reauthorization criteria. Added
coverage criteria for patients previously treated with a biologic
DMARD. Added clarification that submission of medical records is
required documenting current therapy with Orencia in order to bypass
step if claim history not available.
12/2021 Updated conventional DMARD bypass language for rheumatoid
arthritis and psoriatic arthritis with no change to clinical intent. Updated
CT/KY footnote.
3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.
11/2022 Added Enbrel as a preferred step product for RA. Added Enbrel,
Rinvoq, and Xeljanz as preferred step products for PsA. Added Enbrel
and Rinvoq as an example where appropriate. Added Mississippi to
state mandate footnote.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
1/2024 Updated PsA criteria based on updated indication for patients 2 years of
age or older. Updated Background, References, and state mandate
footnote.
© 2025 UnitedHealthcare Services, Inc.
7
2/2024 Removed Olumiant as a preferred product for RA.
10/2024 Updated RA and PsA step requirement noting Adalimumab-adaz
(unbranded Hyrimoz), Amjevita for Nuvaila, and Humira as preferred
adalimumab products with no change to clinical intent. Added
Cosentyx as a step therapy drug for PsA. Removed preferred
adalimumab footnote.
4/2025 Removed examples for adalimumab in step therapy. Changed Stelara
step therapy to “One of the preferred ustekinumab productsc”. Changed
Stelara example to Ustekinumab. Added the footnote “For a list of
preferred products please reference drug coverage tools.”
© 2025 UnitedHealthcare Services, Inc.
8